Literature DB >> 19858306

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.

Arturo Reyes-Sandoval1, Tamara Berthoud, Nicola Alder, Loredana Siani, Sarah C Gilbert, Alfredo Nicosia, Stefano Colloca, Riccardo Cortese, Adrian V S Hill.   

Abstract

Protection against liver-stage malaria relies on the induction of high frequencies of antigen-specific CD8+ T cells. We have previously reported high protective levels against mouse malaria, albeit short-lived, by a single vaccination with adenoviral vectors coding for a liver-stage antigen (ME.TRAP). Here, we report that prime-boost regimens using modified vaccinia virus Ankara (MVA) and adenoviral vectors encoding ME.TRAP can enhance both short- and long-term sterile protection against malaria. Protection persisted for at least 6 months when simian adenoviruses AdCh63 and AdC9 were used as priming vectors. Kinetic analysis showed that the MVA boost made the adenoviral-primed T cells markedly more polyfunctional, with the number of gamma interferon (INF-gamma), tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2) triple-positive and INF-gamma and TNF-alpha double-positive cells increasing over time, while INF-gamma single-positive cells declined with time. However, IFN-gamma production prevailed as the main immune correlate of protection, while neither an increase of polyfunctionality nor a high integrated mean fluorescence intensity (iMFI) correlated with protection. These data highlight the ability of optimized viral vector prime-boost regimens to generate more protective and sustained CD8+ T-cell responses, and our results encourage a more nuanced assessment of the importance of inducing polyfunctional CD8(+) T cells by vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858306      PMCID: PMC2798185          DOI: 10.1128/IAI.00740-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

Review 1.  Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Authors:  Sarah C Gilbert; Vasee S Moorthy; Laura Andrews; Ansar A Pathan; Samuel J McConkey; Jenni M Vuola; Sheila M Keating; Tamara Berthoud; Daniel Webster; Helen McShane; Adrian V S Hill
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

2.  Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance.

Authors:  Anne C Moore; Awen Gallimore; Simon J Draper; Katherine R Watkins; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  A protein particle vaccine containing multiple malaria epitopes.

Authors:  S C Gilbert; M Plebanski; S J Harris; C E Allsopp; R Thomas; G T Layton; A V Hill
Journal:  Nat Biotechnol       Date:  1997-11       Impact factor: 54.908

4.  Immunization of man against sporozite-induced falciparum malaria.

Authors:  D F Clyde; H Most; V C McCarthy; J P Vanderberg
Journal:  Am J Med Sci       Date:  1973-09       Impact factor: 2.378

5.  Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei.

Authors:  R S Nussenzweig; J Vanderberg; H Most; C Orton
Journal:  Nature       Date:  1967-10-14       Impact factor: 49.962

6.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.

Authors:  J Schneider; S C Gilbert; T J Blanchard; T Hanke; K J Robson; C M Hannan; M Becker; R Sinden; G L Smith; A V Hill
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

7.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.

Authors:  M Sedegah; R Hedstrom; P Hobart; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

10.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

Authors:  Daniel P Webster; Susanna Dunachie; Jenni M Vuola; Tamara Berthoud; Sheila Keating; Stephen M Laidlaw; Samuel J McConkey; Ian Poulton; Laura Andrews; Rikke F Andersen; Philip Bejon; Geoff Butcher; Robert Sinden; Michael A Skinner; Sarah C Gilbert; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

View more
  118 in total

Review 1.  HIV vaccines: lessons learned and the way forward.

Authors:  Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Polyfunctional and IFN-γ monofunctional human CD4+ T cell populations are molecularly distinct.

Authors:  Julie G Burel; Simon H Apte; Penny L Groves; James S McCarthy; Denise L Doolan
Journal:  JCI Insight       Date:  2017-02-09

3.  Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Juan Caceres; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2018-04-12       Impact factor: 3.641

4.  Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity.

Authors:  Emily A Thompson; Lalit K Beura; Christine E Nelson; Kristin G Anderson; Vaiva Vezys
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

5.  Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines.

Authors:  Lukas Flatz; Rahul Roychoudhuri; Mitsuo Honda; Abdelali Filali-Mouhim; Jean-Philippe Goulet; Nadia Kettaf; Min Lin; Mario Roederer; Elias K Haddad; Rafick P Sékaly; Gary J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

Review 6.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses against Plasmodium falciparum Antigens after Adenoviral Vaccination.

Authors:  Cyrielle Fougeroux; Louise Turner; Anders Miki Bojesen; Thomas Lavstsen; Peter Johannes Holst
Journal:  J Immunol       Date:  2019-03-04       Impact factor: 5.422

Review 8.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

9.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

10.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.